Ifidancitinib clinical trials
Also written ATI-50002.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses ifidancitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Studies
Open first, then newest update. How each study uses ifidancitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionCompletedPhase 2Aclaris Therapeutics, Inc.NCT03495817Written as ATI-50002How we know
- A Study of ATI-50002 Topical Solution for the Treatment of VitiligoCompletedPhase 2Aclaris Therapeutics, Inc.NCT03468855Written as ATI-50002 topical solutionHow we know
- ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)TerminatedPhase 2Aclaris Therapeutics, Inc.NCT03759340Written as ATI 502 0.46% Topical SolutionHow we know
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)CompletedPhase 2Aclaris Therapeutics, Inc.NCT03315689Written as ATI-50002How we know
- A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataTerminatedPhase 2Aclaris Therapeutics, Inc.NCT03354637Written as ATI-50002 high doseHow we know
- A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisCompletedPhase 2Aclaris Therapeutics, Inc.NCT03585296Written as ATI-502How we know
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataCompletedPhase 2Aclaris Therapeutics, Inc.NCT03551821Written as ATI-50002How we know
Codes
What other systems call ifidancitinib · ClinicalTrials.gg INT017742
- UNII (FDA) R105E71J13IFIDANCITINIBConfirmed FDA, Wikidata
- Wikidata Q105336999ifidancitinibConfirmed FDA, Wikidata
- NCI Thesaurus C174905IfidancitinibOne source FDA
- DrugBank DB16191One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R105E71J13 | IFIDANCITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q105336999 | ifidancitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174905 | Ifidancitinib | One source FDA |
| DrugBank | DB16191 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.